初发系统性红斑狼疮患者外周血CD4^＋CD25^＋Foxp3^＋和CD4^＋CD25^-Foxp3^＋T细胞  

CD4^+CD25^+Foxp3^+ and CD4^+CD25^-Foxp3^+T cells in peripheral blood from new-onset SLE patients

作　　者：张飚[1] 张烜[1] 唐福林[1] 朱立平[2] 刘音[2] 

机构地区：[1]中国医学科学院中国协和医科大学北京协和医院风湿免疫科 [2]中国医学科学院中国协和医科大学基础医学研究所免疫学系,北京100005

出　　处：《中国免疫学杂志》2008年第9期831-836,共6页Chinese Journal of Immunology

基　　金：2005-2007年教育部新世纪优秀人才支持计划(NCET-04-0191);国家自然科学基金(30400410);北京市自然科学基金(7052052)

摘　　要：目的:研究初发系统性红斑狼疮患者(Systemic lupus erythematosus,SLE)外周血CD4+T细胞中CD25和Foxp3表达及其在SLE发病中的意义。方法:根据SLE疾病活动积分(SLEDAI)将初发SLE患者分为活动组(10例)和不活动组(11例),流式细胞仪检测治疗前后外周血CD4+T细胞中CD25、Foxp3和CD127表达百分率,并对其与SLE临床活动度、尿蛋白、补体和anti-ds-DNA相关性进行研究。结果:初发活动组和不活动组SLE患者CD4+CD25+Foxp3+T细胞表达百分率分别为(1.91%~6.75%)和(2.74%~7.01%),与正常对照(2.11%~9.90%)相比没有统计学差异(P=0.524,P=0.794);且初发SLE患者外周血CD4+CD25+T细胞在体外增殖反应和增殖抑制功能与正常对照相比无明显差别(P=0.174,P=0.689);外周血CD4+CD25-Foxp3+T细胞百分率在初发活动组(3.71%~10.94%)和不活动组(2.97%~7.69%)SLE患者均比正常对照(1.01%~3.62%)显著增高(P<0.01和P<0.01);而CD4+CD25+Foxp3-T百分率在初发活动组SLE患者(1.19%~9.23%)显著低于正常对照(2.67%~11.26%)和初发不活动组SLE患者(3.73~8.27%)(P=0.039,P=0.048);与CD4+CD25+Foxp3+T细胞类似,90%左右的CD4+CD25-Foxp3+T细胞不表达或低表达CD127,其百分率与anti-ds-DNA浓度呈正相关,且尽管未达到统计学意义,但激素和免疫抑制治疗后其水平下降。结论:初发未经治疗的SLE患者CD4+CD25+Foxp3+T细胞数量和功能无明显异常,而CD4+CD25-Foxp3+T细胞数量增多,与SLE疾病活动相关,可能具有调节功能。Objective： To investigate the expression of Foxp3 and CD25 on CD4 ^＋ T cells from patients with new-onset systemic lupus erythematosus （SLE） and assess their clinical significance. Methods：Twenty-one new-onset and untreated SLE patients including ten with active （SLEDAI≥ 10） and eleven with inactive disease （SLEDAI≤5） were enrolled in this study.Eleven age-and sex-matched healthy volunteers were also included as controls. Peripheral blood samples were collected and mononuclear cells isolated. The expression of CD25, Foxp3 and CD127 by CD4^＋ T cells was analyzed by flow cytometry （FACS）. Proliferation assays were performed with the isolated CD4^＋ CD25^＋ and/or CD4^＋ CIY25^- T cells. Results： There was no significant difference in number of CD4^＋ CD25^＋ Foxp3^＋T cells in subjects with either active （1.91%-6.75%） or inactive （2.74%- 7.01%） SLE compared to normal controls （2.11%-9.90%）（P = 0.524 and P = 0.794 respectively）, Moreover, suppressive capacity of CD4^＋ CD25^＋ T cells in new-onset lupus patients was not impaired as measured by the capacity to inhibit proliferation of CD4^＋ CD25^- effector T cells （ P = 0. 174, P = 0. 689）. While CD4^＋ CD25^- Foxp3^＋ T cells in both active （3.71% - 10.94%） and inactive （2.97%- 7.69%） patients with new-onset SLE were significantly more frequent than in normal controls （ 1.01%- 3.62 % ） （ P 〈 0.01, respectively）. Similar to CD4^＋ CD25^＋ Foxp^＋ T cells, few of these cells expressed CD127 and positively correlated with the titers of anti-dsDNA antibodies （P =0.029）. Whereas the percentage of CD4^＋ CD25^＋ Foxp3^- T cells in active lupus patients （1.19%- 9.23 % ） was significantly lower than in normal controls （2.67 % - 11.26%, P = 0. 039） and in inactive lupus （3.73 % - 8.27 %, P =0.048）. Treatment with glucocorticoids and cyclophosphamide reduced CD4^＋ CD25^ - Foxp3^＋ T cells in active lupus patients, though there were no statistically significant. Conclusion�

关 键 词：红斑狼疮系统性 CIM CD25 FOXP3 CD127 

分 类 号：R596.2[医药卫生—内科学]